Hepatic and intestinal schistosomiasis: review

Area of Science:

• Tropical medicine
• Parasitology
• Immunology

Background:

• Schistosomiasis is a significant endemic parasitic disease in Egypt, caused by various Schistosoma species.
• Hepatic and intestinal schistosomiasis are the primary chronic forms, leading to severe clinical manifestations.
• Pathogenesis involves host immune responses, granuloma formation, and fibrosis, resulting in complications like portal hypertension and colitis.

Purpose of the Study:

• To provide a comprehensive overview of schistosomiasis in Egypt.
• To discuss the pathogenesis, clinical manifestations, and diagnostic approaches.
• To highlight current treatment strategies and future directions in vaccine development and disease control.

Main Methods:

• Review of existing literature on schistosomiasis epidemiology, pathogenesis, and clinical presentation in Egypt.
• Discussion of diagnostic techniques, including microscopy, serology, and PCR.
• Analysis of treatment options, focusing on praziquantel and ongoing research for vaccines.

Main Results:

• Schistosomiasis presents with hepatic (periportal fibrosis, portal hypertension) and intestinal (colitis, polyps) manifestations.
• Diagnosis is confirmed by microscopy and egg identification, with PCR offering advanced detection capabilities.
• Praziquantel is the current standard treatment, and research is advancing towards vaccine development and control strategies.

Conclusions:

• Effective diagnosis and treatment, particularly with praziquantel, are crucial for managing schistosomiasis.
• Continued research into vaccines and robust preventive programs are essential to control disease morbidity and transmission in Egypt.